Influenza A / B influenza virus antigen detection kit (fluorescence immunochroma
Influenza A / B influenza virus antigen detection kit (fluorescence immunochromatography)

Influenza A / B influenza virus anti✘ ‌gen detection kit (fluorescence immunochro π<♦matography)

Clinical background

   The epidemic of↓÷ influenza (flu) is seasonal and highly co£✘φγntagious, which can easily caus↕≥∏←e widespread epidemics. In the 20th century, t§¶♠hree influenza pandemics occurred in the worΩ♠ld, namely the "Spanish f↓±αlu" caused by H1N1 virα±us in 1918, the "Asian flu" caused by H2N2 ∏±₩€virus in 1957, and the "Hong Kβλ≤ong flu" caused by H3N2 virus in 196 ​→8. In recent years, the flu situation is still vΩ↓₽ery serious. The infection rate inλ≥∏  the severe influenza season from 2017 to™↔§ 2018 reached 7.1%. This data reached a new highε↕ since 2009. During ♦σπthis period, most hospitals were ov≠¥ercrowded and the situation was€₹π grim.
 
  In response to the serio<‍usness of influenza's threat to humans, based o★σ'↓n the fluorescent nanomicrosphere technology pla™£∏tform, our company has broken ∏←≤through the limitations of the low sensφ★itivity of the colloidal gold m׶&ethod and the slow detection of PCR nucleic aci↓¥d methods commonly used in ★ ≈εthe market, becoming a new•γ¶ generation of detection technology.£♦π


First in China

★ National High-tech Research and Development ​ε¥ Plan (863 Plan)
★ Shenzhen's major stra₩¥δπtegic technology researc$ h products
★ With Tsinghua University as the lea™♠π₩der, comprehensively develop products for product‍↕£ion, study, research and application
★ Sensitivity is 10-100 ¥π<times higher than traditional collo©×₽idal gold method
★ Compared with PCR det₹✔εection method, the coincidence σ ‍rate is up to 80%
★ On-site inspection, results in'♣ 15 minutes


Technical principle (fluorescence immunochro‌'matography)


  The samples were added dropwise to​✔ the two wells of the test card§πΩ§s A and B. After the influenza A ♦&and (or) influenza B virus an≤ ®tigens were combined with the fluorescent™←↔" microsphere-labeled influe'≤↑σnza A and (or) influenza¶£← B virus nucleoprotein ₹₹±&monoclonal antibodies After the<  chromatography to the ↑∑test line is captured by the•£ coated antibody, under the 365nm wavel₽∏πength ultraviolet radiat'‍ion, a fluorescent band ap‍πpears, and the influenza A and / or B virusesα$≤ can be determined by naked eyes.


Product advantages
The first in China : the first influenza virus detection product d÷↑σ®eveloped based on fluorescent nanotechn♣¥εology, the technology is nationally leading and
Convenient : it can be used for on-site testing ≥  , which is convenient fβ§σor emergency, outpatient, community hospit‍±☆als and basic hospitals to  שσdevelop
Quickly : a single sample can be completed in 15 minutes
High  sensitivity : 10-100 times higher s↑€✘ensitivity than colloidal gold detecσ¥tion technology,
Strong specificity : no cross-reaction with other respiratory pa←→thogens and other subtypes,
Good stability : intra-batch difference and inter-batch✘₩σ difference <5%

Comparison of clinical methodologi∑∞≥✘es

Detection method

Advantage

limitation

application

PCR detection

High sensitivity and accuracy

Need special laboratory and&nbs‍÷p;

equipment to carry out, 

an experiment process takes 

3-4 hours, high testing cost

Specific patients and 

specific departments

Colloidal gold

Fast, results in 15 minutes

Sensitivity accuracy is li‍$"←mited 

by the technology platform, →$;

low sensitivity, low accuracy, 

high false negative

Preliminary clinical screening, 

as well as the develo•™pment of 

basic hospitals

Virus culture

High accuracy

Long time required, up to ₽λ✘;

6-7 days

Specialized laboratory dia☆↕gnosis

This product
(Fluorescent 

Nanotechnology)

Fast, easy to operate, the results&♣©∏nbsp;

are produced within 15 minutes, 

high sensitivity and accurac↔​קy, and up to 

80% consistency with PCR contβ<rol

Low limitations, no special 

laboratories and equipment 

required

Preliminary clinical screening, 

and the development of 

grassroots hospitals

The need for rapid te ""sting

01. Flu symptoms are generally only fe↓≤≠ver, body pain, sign♣₩"ificant fatigue, and mild respiratory sy↑ mptoms, requiring timely treatment, otherwise itλδ♥↓ is easy to induce o♥✘πther chronic diseases;
02. Most of them can heal without treatγ ↓ment, but for infants and young ♣π↓children with poor resistance, the elderly aα×&≥nd patients with cardiopulmonary diseases, theα↕×®y are prone to death due to seriou$©←s complications such as pneumonia
03. Sudden onset and extremely infeβφ→>ctious. If the patient does not pay aσ"↕"ttention to isolation, it is‍♥ easy to infect peopl <e around them;
04. According to the mechanism of influenza disease♣♠, patients use drugs within 24 h$☆∞σours for best results;
05. Accurate diagnosis to avoid the ©Ω'₽abuse of antibiotics.

Application field
 Clinical, hot c<→•♥linic, emergency test
 Infection sentinel surveillφ₩ance of disease control system, rapid s‍φ→✘creening of epidemic scene
 Influenza A / B screening
 Risk assessment of influenza A / ★≤ΩB
 High-risk groups, n₩✔••ewborn influenza screening
product information
Test specimen: throat swab
Technical principle: fluorescence immunochδ±βromatography
Packing specification: 20 tests/ kit
Validity: 18 months
Applicable instrument: Fluorescence chromatogra≠♣phy test paper interpreter